{"id":"ak001-high-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AK001 binds to Siglec-8, an inhibitory receptor expressed on eosinophils and mast cells, and uses its bispecific design to induce cell death of these effector cells involved in allergic and eosinophilic diseases. By depleting eosinophils and mast cells, the drug reduces the inflammatory cascade characteristic of type 2 immune responses, potentially providing therapeutic benefit in eosinophil-driven and mast cell-driven conditions.","oneSentence":"AK001 is a bispecific antibody that simultaneously engages Siglec-8 on eosinophils and mast cells while cross-linking them to trigger cell death and reduce type 2 inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:20:26.283Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Eosinophilic gastroenteritis"},{"name":"Eosinophilic colitis"},{"name":"Mast cell activation disorder"}]},"trialDetails":[{"nctId":"NCT02734849","phase":"PHASE2","title":"Study to Evaluate Multiple Doses in Patients With Nasal Polyposis","status":"COMPLETED","sponsor":"Allakos Inc.","startDate":"2016-04","conditions":"Nasal Polyposis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AK001 high dose","genericName":"AK001 high dose","companyName":"Allakos Inc.","companyId":"allakos-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AK001 is a bispecific antibody that simultaneously engages Siglec-8 on eosinophils and mast cells while cross-linking them to trigger cell death and reduce type 2 inflammation. Used for Eosinophilic gastroenteritis, Eosinophilic colitis, Mast cell activation disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}